优蜜传媒

skip to main content
优蜜传媒
Nine in 10 Concerned About Rising Drug Costs Due to COVID-19
优蜜传媒

Nine in 10 Concerned About Rising Drug Costs Due to COVID-19

by

Story Highlights

  • Concerns also run high for rising costs of insurance and healthcare
  • Broad support for government negotiation of cost of COVID-19 treatment
  • Over half rate the U.S. response to COVID-19 as fair or poor

This article concerns research conducted in partnership with West Health, a family of nonprofit and nonpartisan organizations focused on lowering healthcare costs for seniors and on the rising cost of healthcare in the U.S.

WASHINGTON, D.C. -- A new study by West Health and 优蜜传媒finds Americans sensitive to a number of negative developments in healthcare that could result from the COVID-19 pandemic. Nearly nine in 10 U.S. adults are "very" (55%) or "somewhat" (33%) concerned that the pharmaceutical industry will leverage the COVID-19 pandemic to raise drug prices. The levels of concern among demographic groups are mostly similar, except by party identification. Democrats (66%) are more likely to say they are very concerned than are independents (52%) or Republicans (49%).

Concern Over Rising Drug Prices in Response to COVID-19
How concerned are you that the pharmaceutical industry will take advantage of the current COVID-19 pandemic to increase drug prices?
  U.S. total Democrats Independents Republicans
  % % % %
Very concerned 55 66 52 49
Somewhat concerned 33 28 35 35
Not at all concerned 12 5 13 16
Gallup-West Health Cost of Healthcare Study, May 2020

These results are based on completed surveys with 1,016 U.S. adults as a part of an ongoing special study by 优蜜传媒and to assess U.S. public opinion on the cost of healthcare. Interviews were conducted May 11-22, 2020.

In addition to concerns over rising drug prices, Americans are also concerned -- to a somewhat lesser extent -- about rising health insurance premiums and the cost of care generally. Overall, 79% are very or somewhat concerned about their health insurance premiums rising and 84% are very or somewhat concerned about the cost of care generally rising, with 41% very concerned about each. The three questions asked were:

  • How concerned are you that the pharmaceutical industry will take advantage of the current COVID-19 pandemic to increase drug prices?

  • How concerned are you that the care required to treat COVID-19 patients will result in increased health insurance premiums next year?

  • How concerned are you that the U.S. health system will take advantage of the current COVID-19 pandemic to increase the cost of care?

Percentage of U.S. Adults "Very Concerned" Over Rising Costs of Prescription Drugs, Insurance, and Healthcare Due to COVID-19 Pandemic
% Very concerned
  Rising drug prices Rising insurance premiums Rising healthcare costs
  % % %
U.S. TOTAL 55 41 41
Gender  
Women 57 46 48
Men 52 37 33
Race  
Nonwhite 59 47 50
White 52 38 36
Annual household income  
Less than $40,000 57 49 46
$40,000-<$100,000 51 37 40
$100,000+ 56 41 38
Party ID  
Democrats 66 49 47
Independents 52 39 43
Republicans 49 37 32
Gallup-West Health Cost of Healthcare Study, May 2020

Differences in key demographic groups are more readily apparent with concerns over rising costs of health insurance and care generally. Nearly half of women (48%), for example, are very concerned about the general cost of care rising, compared with 33% of men. Also, 50% of nonwhites are very concerned, compared with 36% of whites. Across all three measures, Democrats report the highest levels of concern by political identity.

Extensive Support for Government Negotiation of COVID-19 Drug Price

Amid significant concerns about how the COVID-19 pandemic could cause a rise in prices for drugs, insurance and healthcare, a large majority of Americans support direct negotiations by the federal government with the drug manufacturer on the price of a treatment for the disease itself. Nearly nine in 10 (88%) respondents support such an approach, with little differences based on political identity. Significant support exists across all major demographic groups.

Level of Support for Government Negotiation of COVID-19 Treatment Price With Drug Company
If an effective treatment is approved by the FDA for COVID-19, do you think that the federal government should be able to negotiate the price of the treatment with the drug manufacturer?
  Supports government negotiation Opposes government negotiation
  % %
U.S. TOTAL 88 11
Party ID  
Democrats 91 7
Independents 87 12
Republicans 89 11
Gallup-West Health Cost of Healthcare Study, May 2020

Over Half Rate U.S. Response to COVID-19 as Fair or Poor

Concurrent with large-scale support for government pricing negotiation for COVID-19 treatment, evaluations of how the U.S. has responded to the outbreak itself are tepid. When asked to rate the national response to COVID-19 relative to how much the U.S. spends on healthcare, 9% of respondents rate the U.S. response as excellent and another 14% as very good. In contrast, 34% rate the response as poor and 23% as fair.

These evaluations are highly inversely related to both education and income. Among those with postgraduate education, for example, 72% evaluate the response as fair or poor, compared with just 15% who evaluate it as excellent or very good. Political identity also greatly informs perspectives, with 84% of Democrats evaluating the response as fair or poor, compared with 28% of Republicans.

Evaluations of U.S. Response to COVID-19 Relative to Healthcare Expenditures
Relative to how much the U.S. spends on healthcare, do you think that the national response to the COVID-19 outbreak has been excellent, very good, good, fair or poor?
  Excellent/Very good Good Fair/Poor
  % % %
U.S. TOTAL 23 20 57
Education  
Postgraduate 15 12 72
College graduate 15 19 65
Some college 24 19 56
High school or less 27 24 49
Annual household income  
Less than $40,000 23 24 53
$40,000-<$100,000 26 18 56
$100,000+ 19 14 66
Party ID  
Democrats 6 10 84
Independents 20 23 57
Republicans 44 25 28
Gallup-West Health Cost of Healthcare Study, May 2020

Implications

The intersection between the COVID-19 pandemic and the rising cost of healthcare has created wide-ranging ramifications for Americans. Prior West Health/优蜜传媒polling has shown that 14% of Americans experiencing COVID-19 symptoms have been unwilling to seek treatment because of the cost of care, a percentage that is only partially reduced even when infection by the coronavirus is suspected. Two-thirds of Americans, in turn, report an increase in the cost of prescription drugs since 2017, while only 31% report that the Trump administration has made "a great deal" or "a fair amount" of progress on addressing the rising costs of drugs. And 23% report that they lacked the money at least once in the past 12 months for needed prescription drugs. Against this backdrop, the significant concerns about the potential for higher drug prices, health insurance premiums and healthcare as a whole in the wake of the pandemic are understandable.

As Americans brace for a potential second wave of coronavirus infections later this year, leaders would be advised to note that it is not just fear of infection or job loss that is causing concern but also fear of increased costs of prescription drugs, insurance premiums and healthcare generally. Elected officials may as a result consider policy decisions that are designed to curtail these possibilities, assuaging public fears.


优蜜传媒 /poll/312641/nine-concerned-rising-drug-costs-due-covid.aspx
优蜜传媒World Headquarters, 901 F Street, Washington, D.C., 20001, U.S.A
+1 202.715.3030